Compare JKHY & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JKHY | BIO |
|---|---|---|
| Founded | 1976 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1B | 10.1B |
| IPO Year | 2000 | 1994 |
| Metric | JKHY | BIO |
|---|---|---|
| Price | $143.96 | $357.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 20 | 3 |
| Target Price | $190.39 | ★ $328.33 |
| AVG Volume (30 Days) | ★ 831.7K | 230.5K |
| Earning Date | 11-03-2026 | 10-29-2026 |
| Dividend Yield | ★ 1.70% | N/A |
| EPS Growth | 11.86 | ★ 142.61 |
| EPS | ★ 6.98 | N/A |
| Revenue | $1,536,603,000.00 | ★ $2,583,200,000.00 |
| Revenue This Year | $5.90 | N/A |
| Revenue Next Year | $6.92 | $2.47 |
| P/E Ratio | $21.01 | ★ N/A |
| Revenue Growth | ★ 7.37 | 0.65 |
| 52 Week Low | $121.04 | $236.73 |
| 52 Week High | $193.39 | $396.23 |
| Indicator | JKHY | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 37.39 | 48.40 |
| Support Level | $132.36 | $364.41 |
| Resistance Level | $157.59 | $392.81 |
| Average True Range (ATR) | 4.62 | 9.33 |
| MACD | -1.29 | -1.87 |
| Stochastic Oscillator | 13.75 | 33.74 |
Jack Henry is a leading provider of core processing and complementary services, including electronic funds transfer, payment processing, and loan processing, for US banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.